Dopamine D2 receptors as treatment targets in schizophrenia - PubMed (original) (raw)
Review
Dopamine D2 receptors as treatment targets in schizophrenia
Philip Seeman. Clin Schizophr Relat Psychoses. 2010 Apr.
Abstract
The antipsychotic effectiveness of chlorpromazine and haloperidol started a search for their therapeutic targets. The antipsychotic receptor target turned out to be a dopamine receptor, now cloned as the dopamine D2 receptor. The D2 receptor is the common target for antipsychotics. Antipsychotic clinical doses correlate with their affinities for this receptor. Therapeutic doses of antipsychotics occupy 60 to 80% of brain D2 receptors in patients, but aripiprazole occupies up to 90%. While antipsychotics may take up to six hours to occupy D2 receptors, much clinical improvement occurs within a few days. The receptor has high- and low-affinity states. The D2High state is functional for dopamine-like agonists such as aripiprazole. Most individuals with schizophrenia are supersensitive to dopamine. Animal models of psychosis show that a variety of risk factors, genetic and nongenetic, are associated with behavioral supersensitivity to dopamine, reflected in elevated levels of dopamine D2High receptors. Although antipsychotics such as haloperidol alleviate psychosis and reverse the elevation of D2High receptors, long-term use of traditional antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic such as aripiprazole can result in the emergence of psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism and rarely result in tardive dyskinesia because they are released from D2 within 12 to 24 hours. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2High receptors and desensitizing them in early-stage psychosis.
Similar articles
- Psychosis pathways converge via D2high dopamine receptors.
Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T. Seeman P, et al. Synapse. 2006 Sep 15;60(4):319-46. doi: 10.1002/syn.20303. Synapse. 2006. PMID: 16786561 Review. - Atypical antipsychotics: mechanism of action.
Seeman P. Seeman P. Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review. - All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P. Seeman P. CNS Neurosci Ther. 2011 Apr;17(2):118-32. doi: 10.1111/j.1755-5949.2010.00162.x. CNS Neurosci Ther. 2011. PMID: 20560996 Free PMC article. - Are dopamine D2 receptors out of control in psychosis?
Seeman P. Seeman P. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:146-52. doi: 10.1016/j.pnpbp.2013.07.006. Epub 2013 Jul 21. Prog Neuropsychopharmacol Biol Psychiatry. 2013. PMID: 23880595 Review. - Schizophrenia and dopamine receptors.
Seeman P. Seeman P. Eur Neuropsychopharmacol. 2013 Sep;23(9):999-1009. doi: 10.1016/j.euroneuro.2013.06.005. Epub 2013 Jul 13. Eur Neuropsychopharmacol. 2013. PMID: 23860356 Review.
Cited by
- Cognitive Effects of Reducing First-Generation Antipsychotic Dose Compared to Switching to Ziprasidone in Long-Stay Patients with Schizophrenia.
Bogers JPAM, Blömer JA, de Haan L. Bogers JPAM, et al. J Clin Med. 2024 Apr 4;13(7):2112. doi: 10.3390/jcm13072112. J Clin Med. 2024. PMID: 38610877 Free PMC article. - Neurobiochemical Disturbances in Psychosis and their Implications for Therapeutic Intervention.
Panov G, Panova P. Panov G, et al. Curr Top Med Chem. 2024;24(20):1784-1798. doi: 10.2174/0115680266282773240116073618. Curr Top Med Chem. 2024. PMID: 38265370 Review. - Optical Control of Dopamine D2-like Receptors with Cell-Specific Fast-Relaxing Photoswitches.
Hetzler BE, Donthamsetti P, Peitsinis Z, Stanley C, Trauner D, Isacoff EY. Hetzler BE, et al. J Am Chem Soc. 2023 Aug 30;145(34):18778-18788. doi: 10.1021/jacs.3c02735. Epub 2023 Aug 16. J Am Chem Soc. 2023. PMID: 37586061 Free PMC article. - Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S. Isaacson SH, et al. Clin Park Relat Disord. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. Clin Park Relat Disord. 2023. PMID: 37497384 Free PMC article. Review. - The Natural Protoalkaloid Methyl-2-Amino-3-Methoxybenzoate (MAM) Alleviates Positive as well as Cognitive Symptoms in Rat and Mouse Schizophrenia Models.
Bright Y, Maas DA, Verheij MMM, Paladini MS, Amatdjais-Groenen HIV, Molteni R, Riva MA, Martens GJM, Homberg JR. Bright Y, et al. Curr Neuropharmacol. 2024;22(2):323-338. doi: 10.2174/1570159X21666230720122354. Curr Neuropharmacol. 2024. PMID: 37475559 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical